Abstract: Method, composition and system for generating chlorine dioxide gas in a controlled release manner by combining at least one metal chlorite and a dry solid hydrophilic material that reacts with the metal chlorite in the presence of water vapor, but does not react with the metal chlorite in the substantial absence of liquid water or water vapor to produce chlorine dioxide gas in a sustained amount of from about 0.001 to 1,000 ppm.

Abstract: The invention relates to a process for the catalytic interesterification of triglycerides, which is characterized in that a heterogeneous catalyst is used, based on one or more oxides and/or oxysalts of metals of the groups IA and IIA of the Periodic System, at least one of the oxides and/or oxysalts having an optical basicity .LAMBDA. which is at least 0.5.

Abstract: Novel gas separation agents with precisely and predictably controlled pore sizes within the range of 3-4 Angstrom units and their preparation from ETS-4 by exchange with cations, particularly multivalent cations such as strontium followed by drying and calcination to effect controlled pore shrinkage is disclosed. These novel materials have utility in gas separation processes particularly the separation of nitrogen from a mixture of the same with methane.

Abstract: A catalyst for oxidizing carbon monoxide in a gas stream is provided. The catalyst contains a combination of a platinum component and one or more bismuth oxides in amounts sufficient to convert carbon monoxide to carbon dioxide in the presence of oxygen. The bismuth oxides inhibit the tendency of the platinum to convert SO.sub.2 in the gas stream, if any, to SO.sub.3. The atomic molar ratio of bismuth to platinum is preferably in the range of from about 0.1:1 to 6:1.

Abstract: Method of catalytically activating the surface of a heat exchange device while retaining the heat exchange properties of the device and heat exchange devices obtained thereby.

Abstract: A method for producing ice having substantially no undesirable taste and odor characteristics is disclosed.

Abstract: A process for hydrodehalogenating halogenated organic compounds present in a contaminated aqueous environmental source in which the halogenated organic compounds are reacted with hydrogen gas or a source of hydrogen gas in the presence of a catalyst of palladium on carbon.

Abstract: A process for hydrodehalogenating halogenated aromatics present in a contaminated aqueous environmental source in which the halogenated aromatics are reacted with hydrogen gas or a source of hydrogen gas in the presence of a basic proton acceptor and a catalyst of palladium on carbon.

Abstract: Individuals are aided in smoking cessation by administering internally phenylpropanolamine.

Abstract: A method of enhancing transdermal delivery of a pharmaceutically active drug from a transdermal delivery system as well as a transdermal delivery system capable of providing a desirable flow interface between the delivery system and the skin surface are disclosed. The method involves pre-treating an area of skin with an anticholinergic agent in an amount sufficient to have a local antisecretory effect on the area treated, such amount being insufficient to cause systemic effects; and applying the transdermal delivery system to the pre-treated area. The delivery system of the present invention is comprised of a carrier means, a pharmaceutically active drug and an anticholinergic agent. With both the method and the delivery system, the anticholinergic agent is preferably a quaternary ammonium salt which is itself transdermally delivered to the area beneath the delivery system in an amount sufficient to suppress perspiration in that area.

Abstract: A multistep process is disclosed for preparing azetidinone intermediates used in the making penems and carbapenems wherein intermediates containing ##STR1## R' is independently hydrogen or 1, 2 or 3 of lower alkyl or lower alkoxy, preferably hydrogen, wherein R" is methyl, ethyl, a phenyl or alkyl, preferably ethyl, as a readily removable nitrogen protecting group are made.

Abstract: A long acting diltiazem formulation is disclosed that comprises more than 35 percent by weight of a swellable hydrophilic polymer.Release rate is also controlled by the application of diffusion controlled membrane to the matrix tablet containing swellable hydrophilic polymers. The diffusion rate through the membrane depends upon the composition or ratio of hydrophilic to hydrophobic coating agent.

Abstract: An immediate release diltiazem tablet is disclosed that exhibits an unexpectedly rapid bioavailability profile when the active ingredient is diltiazem.

Abstract: A method for producing a compound of the formula ##STR1## wherein: R.sup.1, R.sup.11 and R.sup.12 may be the same or different and each is hydrogen or alkyl;Q is methylene, --O-- or --S--;m and n are independently variable and may each have a value of 0, 1 or 2;X is hydrogen, halo, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, hydroxy, alkoxy or trifluoromethyl;Y is hydrogen, hydroxy, alkoxy, ##STR2## --N(R.sup.1).sub.2, ##STR3## where R.sup.1 is as defined above; ring t represents a fused thiophene or fused benzene ring, said fused benzene ring optionally being substituted with a substituent Z as defined below; andZ is X as defined above, amino, alkylamino or ##STR4## {wherein R.sup.10 is hydrogen, alkyl or aryl}, comprising reacting a compound of formula II or formula III ##STR5## with a compound of the formula where Hal is a halogen; andR.sup.13 is acetyl, or Si(R.sup.14).sub.3 where each R.sup.14 independently is alkyl or aryl is disclosed.

Abstract: Pharmaceutical compositions for use in the treatment of cough/cold symptoms comprising loratadine, ibuprofen and pseudoephedrine are disclosed.

Abstract: Novel polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives are disclosed which are useful for treating allergic reactions, inflammation, peptic ulcers, hypertension, and hyperproliferative skin diseases and for suppressing the immune response in mammals. Methods for preparing said compounds are also disclosed.

Abstract: A process for preparing aqueous parenteral compositions of drugs which are weak bases and are only slightly soluble in water is disclosed. Aqueous parenteral compositions of the antifungal agent (.+-.) (2R*, 3R*)-2-(2,4-difluorophenyl)-3-methylsulfonyl-1-(1,2,4-triazol-1-yl)butan-2 -ol are also disclosed.

Abstract: Pharmaceutical preparations comprised of a pharmaceutically active ingredient and a carrier which comprises a percutaneous penetration enhancer comprised of 2-ethyl-1, 3-hexanediol alone or in combination with oleic acid is disclosed. The 2-ethyl-1, 3-hexanediol may be present in an amount in the range of about 50% to 100% based on the weight of the carrier. The oleic acid may be used in combination with 2-ethyl-1, 3-hexanediol in an amount of about 1 to 40% based on the weight of the carrier to provide a synergistic effect with respect to percutaneous penetration enhancement. The compound 2-ethyl-1, 3-hexanediol as used alone and/or in combination with the oleic acid has been found to significantly enhance the delivery of a drug, to a patient, from a transdermal delivery system.

Abstract: This invention relates to monoclonal antibodies to interferon alpha and to hybridomas producing such antibodies. These antibodies are preferably of the immunoglobulin subclass IgGl and preferably do not bind to alpha or alpha interferon. They can be used in assaying, purifying or isolating proteins, such as interferon alpha, for which they are specific.